In re Maxim Integrated Products, Inc.

867 F. Supp. 2d 1333, 2012 WL 2126807
United States Judicial Panel on Multidistrict Litigation·Decided June 11, 2012·No. MDL No. 2354·Published·Cited by 15 cases

Opinion

CORRECTED TRANSFER ORDER

W. ROYAL FURGESON, JR., Acting Chairman.

Before the Panel: * Pursuant to 28 U.S.C. § 1407, patentholder Maxim Integrated Products, Inc. (Maxim) seeks centralization in the Eastern District of Texas. This litigation currently consists of the fourteen actions, pending in five districts, listed on Schedule A.1

All responding parties oppose centralization. Various parties2 alternatively suggest selection of the Northern District of California as the transferee district. Declaratory judgement plaintiffs PNC and Vanguard3 and Eastern District of Texas defendant QVC, Inc. suggest selection of the Western District of Pennsylvania. De[1334] claratory judgment plaintiff Jack Henry & Assocs. and defendant First United Bank & Trust Co. suggest selection of the District of Kansas as the transferee forum or, alternatively, the Northern District of California. Regardless of their stated forum preference, these responding parties do not oppose centralization in any of the suggested transferee forums (but they specifically oppose selection of the Eastern District of Texas).

Maxim is the owner by assignment from Dallas Semiconductor (a wholly owned subsidiary of Maxim reportedly purchased in 2001) of five patents related to mobile commerce.4 Specifically, the patents are directed to various systems and methods for performing secure transactions using mobile devices and also involve secure exchanges of information using mobile encryption and decryption and related capabilities. The actions currently before the Panel are infringement actions brought by Maxim or declaratory judgment actions brought by various parties that Maxim has asserted have infringed the patents.

The responding parties uniformly oppose centralization, principally arguing that any common factual issues among the actions are subsumed by unique factual issues presented by each defendant, including questions of contributory or induced infringement. There could very well be some variances in terms of the technology employed with the various defendants’ respective mobile applications or the circumstances surrounding the alleged infringement, but “[tjransfer under Section 1407(a) does not require a complete identity or even a majority of common factual or legal issues as a prerequisite to transfer.” See In re Rembrandt Techs., LP, Patent Litig., 493 F.Supp.2d 1367, 1369 (J.P.M.L. 2007). The fourteen actions before us involve common factual questions concerning the background of the patents and the subject matter (i.e., mobile applications performing secured transactions); yet, respondents appear to desire an opportunity to advance multiple, individualized — and possibly conflicting — invalidity positions that are informed by multiple non-infringement theories. We are of the view that centralization can meaningfully reduce the number of potentially inconsistent rulings and create significant efficiencies over respondents’ proposed fragmented approach. Centralization will place all actions before a single judge who can preside over discovery relating to the common patents, which will inform and aid the consistent construction of the patents’ claims. The transferee judge can further rule on all challenges to the validity of the patents (and accommodate such matters as a post-grant review of some of the patents’ business method claims, which defendants note can be made with the Patent and Trademark Office after September 17, 2012, pursuant to Section 18 of the America Invents Act (AIA)) and otherwise streamline the pretrial proceedings.

Respondents also argue that the AIA is incompatible with centralization. While we recently held that “the America Invents Act does not alter our authority to [1335] order pretrial centralization of this litigation,” see In re Bear Creek Techs., Inc. (’722) Patent Litig., 858 F.Supp.2d 1375, 1377-78, 2012 WL 1523340, *2 (J.P.M.L. 2012), respondents correctly note that the AIA’s right to separate trials should be taken into account when making the decision to centralize a given litigation, inasmuch as the AIA is the new reality in patent litigation and its right to separate trials could impact the Panel’s calculus regarding whether centralization benefits “the convenience of parties and witnesses” and “will promote the just and efficient conduct” of the litigation. 28 U.S.C. § 1407(a).

While the AIA changed the landscape of patent litigation — particularly the filing of actions against multiple unrelated defendants and the right to a separate trial when defendants are only accused of violating the same patent — it does not follow that the mere possibility of factual disputes regarding a particular invalidity defense or the infringement of a particular product that might need to be presented to a jury (or juries) is sufficient to deny centralization of actions otherwise involving common factual questions. Nor should such a determination automatically trump the pretrial efficiencies (notably in having a single judge construe the patent’s claims, as opposed to five judges in various districts) that can be gained from centralizing this litigation.

Respondents are also wrong to read into Section 1407 a requirement that the proponent of centralization in patent litigation prove to the Panel that any factual disputes regarding common factual questions will be resolved diming pretrial proceed; ings. As the Panel held long ago, “[t]he framers of Section 1407 did not contemplate that the Panel would decide the merits of the actions before it and neither the statute nor the implementing Rules of the Panel are drafted to allow for such determinations.” In re Kauffman Mut. Fund Actions, 337 F.Supp. 1337, 1339-40 (J.P.M.L.1972).

As this litigation progresses, whether the actions are appropriate for trial, and upon what issues, will become more apparent to the transferee judge than here to the Panel at the outset of these cases, all of which were filed earlier this year. The rights afforded defendants under the joinder and trial consolidation provisions of the AIA may play a role in the transferee judge’s conduct of the MDL proceedings, including the judge’s determination of when a remand to the transferor court may be appropriate. For instance, prompt remand after the common claims are construed and summary judgment addressed on certain common invalidity grounds may be appropriate. But we need not decide the exact course of this litigation now. As always, we trust such matters to the sound judgment of the transferee judge.

Free access — add to your briefcase to read the full text and ask questions with AI

In re Maxim Integrated Products, Inc., 867 F. Supp. 2d 1333, 2012 WL 2126807 (jpml 2012).

867 F. Supp. 2d 1333 (In re Maxim Integrated Products, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Wright v. AT&T
D. Montana, 2025
Hart v. T-Mobile U.S. Inc.
N.D. California, 2023
In re Allura Fiber Cement Siding Prods. Liab. Litig.
366 F. Supp. 3d 1365 (Judicial Panel on Multidistrict Litigation, 2019)
Untitled Case
C.D. California, 2018
In re Uber Techs., Inc., Data Sec. Breach Litig.
304 F. Supp. 3d 1351 (Judicial Panel on Multidistrict Litigation, 2018)
In re Fluoroquinolone Products Liability Litigation
122 F. Supp. 3d 1378 (Judicial Panel on Multidistrict Litigation, 2015)
Global Touch Solutions, LLC v. Toshiba Corp.
109 F. Supp. 3d 882 (E.D. Virginia, 2015)
In re Xarelto (Rivaroxaban) Products Liability Litigation
65 F. Supp. 3d 1402 (Judicial Panel on Multidistrict Litigation, 2014)
In re New England Compounding Pharmacy, Inc. Products Liability Litigation
38 F. Supp. 3d 1384 (Judicial Panel on Multidistrict Litigation, 2014)
In re TLI Communications LLC Patent Litigation
26 F. Supp. 3d 1396 (Judicial Panel on Multidistrict Litigation, 2014)
In re BRCA1- & BRCA2-based Hereditary Cancer Test Patent Litigation
999 F. Supp. 2d 1377 (Judicial Panel on Multidistrict Litigation, 2014)
In re Anheuser-Busch Beer Labeling Marketing & Sales Practices Litigation
949 F. Supp. 2d 1371 (Judicial Panel on Multidistrict Litigation, 2013)
In re Body Science LLC Patent Litigation
883 F. Supp. 2d 1344 (Judicial Panel on Multidistrict Litigation, 2012)
In re Unified Messaging Solutions LLC Patent Litigation
883 F. Supp. 2d 1340 (Judicial Panel on Multidistrict Litigation, 2012)